DK1385498T3 - Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler - Google Patents

Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler

Info

Publication number
DK1385498T3
DK1385498T3 DK02761857T DK02761857T DK1385498T3 DK 1385498 T3 DK1385498 T3 DK 1385498T3 DK 02761857 T DK02761857 T DK 02761857T DK 02761857 T DK02761857 T DK 02761857T DK 1385498 T3 DK1385498 T3 DK 1385498T3
Authority
DK
Denmark
Prior art keywords
neutrophils
survival
fatty acids
activation factors
activation
Prior art date
Application number
DK02761857T
Other languages
Danish (da)
English (en)
Inventor
Jean Barabe
Christopher Penney
Pierre Laurin
Lyne Gagnon
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Application granted granted Critical
Publication of DK1385498T3 publication Critical patent/DK1385498T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02761857T 2001-04-18 2002-04-18 Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler DK1385498T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28445801P 2001-04-18 2001-04-18
PCT/CA2002/000535 WO2002083120A2 (en) 2001-04-18 2002-04-18 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors

Publications (1)

Publication Number Publication Date
DK1385498T3 true DK1385498T3 (da) 2008-03-25

Family

ID=23090294

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02761857T DK1385498T3 (da) 2001-04-18 2002-04-18 Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler
DK07116425.5T DK1900364T3 (da) 2001-04-18 2002-04-18 Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07116425.5T DK1900364T3 (da) 2001-04-18 2002-04-18 Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer

Country Status (30)

Country Link
US (2) US7745488B2 (enExample)
EP (2) EP1385498B1 (enExample)
JP (3) JP5026655B2 (enExample)
KR (1) KR20030096323A (enExample)
CN (1) CN1633286A (enExample)
AP (1) AP1740A (enExample)
AU (2) AU2002308456B2 (enExample)
BG (1) BG66418B1 (enExample)
BR (1) BR0208984A (enExample)
CA (2) CA2444463C (enExample)
CY (1) CY1107081T1 (enExample)
CZ (1) CZ305273B6 (enExample)
DE (1) DE60223670T2 (enExample)
DK (2) DK1385498T3 (enExample)
EA (1) EA007322B1 (enExample)
EE (1) EE200300510A (enExample)
ES (2) ES2295397T3 (enExample)
HU (1) HUP0303817A3 (enExample)
IL (3) IL158322A0 (enExample)
MX (1) MXPA03009436A (enExample)
NO (1) NO335105B1 (enExample)
NZ (2) NZ541140A (enExample)
OA (1) OA12506A (enExample)
PL (2) PL223348B1 (enExample)
PT (2) PT1900364E (enExample)
SI (1) SI1385498T1 (enExample)
SK (1) SK12772003A3 (enExample)
TN (1) TNSN03089A1 (enExample)
WO (1) WO2002083120A2 (enExample)
ZA (1) ZA200307778B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444463C (en) 2001-04-18 2012-03-20 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
DE04708802T1 (de) * 2003-02-07 2006-06-22 Prometic Biosciences Inc., Montreal Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
DE602004006137T3 (de) 2003-07-25 2012-01-19 Prometic Biosciences Inc. Herstellung von metallsalzen von fettsäuren mit mittlerer kettenlänge
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CA2578993A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
NZ554176A (en) 2004-10-01 2010-04-30 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
EP1858912B1 (en) * 2005-02-28 2012-04-11 Alphabeta AB Compounds for reducing aggregation of amyloid beta-peptide
CA2687446A1 (en) * 2006-05-17 2007-11-29 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
PT2299998T (pt) 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
EP2231166B1 (en) * 2007-12-19 2013-03-20 ProMetic BioSciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
EP2165713B1 (en) * 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
JP2013500966A (ja) 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
RU2646823C2 (ru) 2013-08-19 2018-03-07 Энзикем Лайфсайенсиз Корпорейшн Композиция для предотвращения или лечения ревматоидного артрита, содержащая в качестве активного ингредиента моноацетилдиглицерид
KR20180015297A (ko) * 2014-05-15 2018-02-12 주식회사 엔지켐생명과학 백혈구 감소증 및 혈소판 감소증에 대한 치료 방법
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
US9808438B2 (en) 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
TWI749016B (zh) 2016-06-08 2021-12-11 董宇紅 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN107382710B (zh) * 2017-08-19 2020-11-06 中国铁道科学研究院集团有限公司铁道建筑研究所 一种接枝抗氧剂分子的多元醇
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
KR102054401B1 (ko) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
WO2021085144A1 (ja) * 2019-10-31 2021-05-06 日本ゼオン株式会社 電気化学素子用機能層およびその製造方法、電気化学素子用機能層付きセパレータおよびその製造方法、並びに電気化学素子およびその製造方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023067501A1 (en) * 2021-10-18 2023-04-27 Enzychem Lifesciences Corporation Compositions and methods for treating mucositis
US20250270471A1 (en) * 2022-04-21 2025-08-28 Merck Sharp & Dohme Llc Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4703062A (en) * 1984-01-16 1987-10-27 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH02134326A (ja) * 1988-11-14 1990-05-23 Snow Brand Milk Prod Co Ltd 高度侵襲用経腸栄養剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2081104A1 (en) * 1991-02-22 1992-08-23 Glenn Pierce Use of gm-csf and g-csf to promote accelerated wound healing
JP3132085B2 (ja) * 1991-09-06 2001-02-05 ウェルファイド株式会社 脂肪乳剤
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) * 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
ATE230262T1 (de) * 1995-11-28 2003-01-15 Braun Melsungen Ag Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) * 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6017531A (en) * 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
JP2001514209A (ja) 1997-09-04 2001-09-11 バイオゾーン ラボラトリーズ，インコーポレイテッド 経口リポソーム送達系
WO1999025312A1 (en) * 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
EP1061932B1 (en) * 1997-11-20 2006-01-25 Gil Ja Jhon Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2001022937A1 (en) * 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ATE341331T1 (de) * 2000-06-14 2006-10-15 William Leslie Porter Lipide zur änderung des abwehrsystems
CN100348183C (zh) * 2000-06-20 2007-11-14 营养科学公司 可用作抗微生物剂的中链脂肪酸
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
CA2444463C (en) 2001-04-18 2012-03-20 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
DE04708802T1 (de) 2003-02-07 2006-06-22 Prometic Biosciences Inc., Montreal Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
DE602004006137T3 (de) 2003-07-25 2012-01-19 Prometic Biosciences Inc. Herstellung von metallsalzen von fettsäuren mit mittlerer kettenlänge
CA2578993A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
AP1740A (en) 2007-05-10
AU2006201163A1 (en) 2006-04-13
EP1385498A2 (en) 2004-02-04
SI1385498T1 (sl) 2008-04-30
NZ528690A (en) 2005-08-26
EP1900364A3 (en) 2009-09-23
AP2003002888A0 (en) 2003-12-31
CA2763637A1 (en) 2002-10-24
US7745488B2 (en) 2010-06-29
KR20030096323A (ko) 2003-12-24
WO2002083120A3 (en) 2003-05-22
CZ20032685A3 (cs) 2004-06-16
IL158322A0 (en) 2004-05-12
IL158322A (en) 2011-09-27
BG66418B1 (bg) 2014-03-31
WO2002083120A2 (en) 2002-10-24
PL366435A1 (en) 2005-01-24
CA2444463A1 (en) 2002-10-24
BG108280A (bg) 2004-09-30
ES2295397T3 (es) 2008-04-16
JP2014231519A (ja) 2014-12-11
CN1633286A (zh) 2005-06-29
PL223348B1 (pl) 2016-10-31
CA2763637C (en) 2016-08-23
PL222876B1 (pl) 2016-09-30
AU2006201163B2 (en) 2006-10-05
US20040147599A1 (en) 2004-07-29
BR0208984A (pt) 2004-06-29
EP1900364B1 (en) 2013-09-25
IL195200A0 (en) 2009-08-03
DE60223670D1 (de) 2008-01-03
NZ541140A (en) 2006-11-30
NO335105B1 (no) 2014-09-15
JP6420089B2 (ja) 2018-11-07
ZA200307778B (en) 2004-04-21
OA12506A (en) 2006-05-29
SK12772003A3 (sk) 2004-07-07
HUP0303817A2 (hu) 2004-03-01
IL195200A (en) 2011-11-30
MXPA03009436A (es) 2004-12-06
US20100279959A1 (en) 2010-11-04
JP2010053135A (ja) 2010-03-11
NO20034644L (no) 2003-11-25
HUP0303817A3 (en) 2009-10-28
NO20034644D0 (no) 2003-10-17
AU2002308456B2 (en) 2005-12-22
CA2444463C (en) 2012-03-20
EP1900364A2 (en) 2008-03-19
JP5657879B2 (ja) 2015-01-21
ES2439738T3 (es) 2014-01-24
EP1385498B1 (en) 2007-11-21
CZ305273B6 (cs) 2015-07-15
PT1900364E (pt) 2013-12-19
EE200300510A (et) 2004-02-16
JP5026655B2 (ja) 2012-09-12
PT1385498E (pt) 2007-12-14
CY1107081T1 (el) 2012-10-24
DK1900364T3 (da) 2014-01-13
JP2004525957A (ja) 2004-08-26
DE60223670T2 (de) 2008-03-06
PL402948A1 (pl) 2013-05-13
EA200301131A1 (ru) 2004-04-29
TNSN03089A1 (en) 2005-12-23
EA007322B1 (ru) 2006-08-25
US8487001B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
DK1385498T3 (da) Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler
DE60127649D1 (de) Antriebssteuereinrichtung
DE60134423D1 (de) Flammhemmende polycarbonat-polyester zusammensetzung
DE50102748D1 (de) Antriebseinheit
NO20031797D0 (no) Heteroarylalkylpiperazinderivater som fettsyreoksydasjonsinhibitorer
DE60109777D1 (de) Plattenlaufwerk
EP1190945A4 (en) AIRCRAFT ENVIRONMENT CONTROLLER
NO20032272D0 (no) Bifenylkarboksamider nyttige som lipidsenkende midler
DE10193827D2 (de) Wischerantrieb
DE50005268D1 (de) Verzweigte weitgehend ungesättigte fettalkoholsulfate
NO20001294D0 (no) Måler for skyvekraft
FI20001733L (fi) Refraktometri
DK1317426T3 (da) Betal-thio-aminosyrer
NO20020457L (no) Benzenaminderivater som antikoagulanter
FR2805501B1 (fr) Appui-tete
DE60117388D1 (de) Nahrungsergänzungsmittel
DE50109499D1 (de) Scheibenwischerantrieb
DE50006610D1 (de) Verzweigte, weitgehend ungesättigte fettalkohole
DE50103920D1 (de) Werkstück
DE50110467D1 (de) Staffelei
ES1053121Y (es) Soporte para perfumes y productos similares.
DE60038983D1 (de) Sparsames hydraulisches miniaturbetätigungsglied
DE50113683D1 (de) Querträger
SE0101214D0 (sv) Oxetane-caprolactone ester
FI20000233A0 (fi) Järjestely tuotteiden esille panemiseksi